NESS ZIONA, Israel, Jan. 2,
2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd.
(Nasdaq: BVXV) (TASE: BVXV), developer of M-001, the Universal Flu
Vaccine candidate currently in preparation for a Phase 3 clinical
trial, announced today that one of its key patents titled "A
Synthetic or Recombinant Influenza Multi-Epitope Polypeptide" has
been granted in India. The patent
belongs to BiondVax's portfolio family titled "Multimeric
Multi-Epitope Influenza Vaccines" and has now been granted in over
30 countries.
With a population of over 1.3 billion people, and high
population density in some of the major cities, India is an important potential market for
BiondVax and a universal flu vaccine may significantly improve
public health.
Dr. Tamar Ben-Yedidia, CSO
of BiondVax, commented, "We are pleased and thankful that the
Government of India's Patent
Office accepted the uniqueness of our universal flu vaccine
solution and approved this main patent of
BiondVax. Authorities worldwide recognize that currently
marketed influenza vaccines fall short. I am proud that M-001,
which is designed to cover current, future, seasonal and pandemic
flu strains, is preparing to enter Phase 3 trials later in
2018."
There is a general recommendation for seasonal influenza
vaccination in India for
healthcare workers, pregnant women, and people with some chronic
illnesses.[1] However, Northern and Southern Hemisphere flu strains
dominate at different times and in different regions of the Indian
subcontinent. A universal flu vaccine, designed to cover all flu
strains, would provide consistent coverage, and be appropriate for
vaccination throughout the year.
The patent describes influenza vaccines comprised of multiple
copies of several epitopes, such as M-001 which contains nine
common and conserved influenza virus epitopes.
About BiondVax Pharmaceuticals Ltd
BiondVax is an
advanced clinical stage biopharmaceutical company developing a
universal flu vaccine. The vaccine candidate, called M-001, is
designed to provide multi-season protection against current and
future, seasonal and pandemic influenza virus strains. BiondVax's
proprietary technology utilizes a unique combination of conserved
and common influenza virus peptides, activating both arms of the
immune system for a cross-protecting and long-lasting effect. In a
total of 6 completed Phase 1/2 and Phase 2 human clinical trials,
covering 698 participants, the vaccine has been shown to be safe,
well-tolerated, and immunogenic. BiondVax is traded on NASDAQ: BVXV
and TASE: BVXV. Please visit www.biondvax.com.
Forward Looking Statements
This press release
contains forward-looking statements within the meaning of the
Private Litigation Reform Act of 1995. Words such as "expect,"
"believe," "intend," "plan," "continue," "may," "will,"
"anticipate," and similar expressions are intended to identify
forward-looking statements. These forward-looking statements
involve certain risks and uncertainties reflect the management's
current views with respect to certain current and future events and
are subject to various risks, uncertainties and assumptions that
could cause the results to differ materially from those expected by
the management of BiondVax Pharmaceuticals Ltd. risks and
uncertainties include, but are not limited to, the risk that drug
development involves a lengthy and expensive process with uncertain
outcome; the ability of the Company to maintain, preserve and
defend its intellectual property and patents granted; whether
our vaccine candidate will successfully advance through the
clinical trial process on a timely basis, or at all, and receive
approval from the United States Food and Drug
Administration or equivalent foreign regulatory agencies; the
adequacy of available cash resource and the ability to raise
capital when needed. More detailed information about the risks
and uncertainties affecting the Company is contained under the
heading "Risk Factors" in our Annual Report on Form 20-F for the
year ended December 31, 2016 filed
with the U.S. Securities and Exchange Commission, or SEC, which is
available on the SEC's website, www.sec.gov, and in the
Company's periodic filings with the SEC and the Tel-Aviv Stock
Exchange.
[1] Government of India,
Ministry of Health & Family Welfare, "Seasonal Influenza:
Guidelines for Vaccination with Influenza Vaccine", 25 April 2017.
For further information, please contact:
BiondVax
Joshua
Phillipson
+972-8-930-2529 x5105
j.phillipson@biondvax.com
View original
content:http://www.prnewswire.com/news-releases/biondvax-universal-flu-vaccine-patent-granted-in-india-300576389.html
SOURCE BiondVax Pharmaceuticals Ltd.